A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Maria BrambatiChiara GiuffrèAlessandro MarcheseFrancesco Maria BandelloGiulio Maria ModoratiElisabetta MiserocchiPublished in: European journal of ophthalmology (2020)
We report a case of ocular drug toxicity consistent with bilateral Vogt-Koyanagi-Harada (VKH) like disease in a patient with cutaneous melanoma treated with Dabrafenib/Trametinib therapy. A 53-year-old man with a history of metastatic cutaneous melanoma, treated with Dabrafenib/Trametinib, developed a severe acute panuveitis with granulomatous anterior uveitis and multiple serous retinal detachments. The ocular inflammatory reaction was classified as a bilateral Vogt-Koyanagi-Harada disease. Intraocular inflammation resolved after discontinuation of chemotherapeutic agents and aggressive topical and systemic corticosteroid therapy. The present case outlines the importance of recognizing VKH-like syndrome as a possible consequence of therapy with dabrafenib and trametinib.
Keyphrases
- case report
- oxidative stress
- squamous cell carcinoma
- small cell lung cancer
- ankylosing spondylitis
- juvenile idiopathic arthritis
- skin cancer
- rheumatoid arthritis
- systemic lupus erythematosus
- bone marrow
- optical coherence tomography
- systemic sclerosis
- disease activity
- electronic health record
- cataract surgery
- replacement therapy